Voloridge Investment Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Voloridge Investment Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-8,432	Closed	-$393K	–	1714
2020 Q4	$393K	Buy	8,432 +3,679	+77%	+$172K	﹤0.01%	1175
2020 Q3	$202K	Sell	4,753 -14,043	-75%	-$614K	﹤0.01%	1194
2020 Q2	$902K	Sell	18,796 -7,413	-28%	-$370K	0.01%	886
2020 Q1	$1.21M	Sell	26,209 -4,602	-15%	-$231K	0.03%	462
2019 Q4	$1.85M	Buy	+30,811	New	+$1.84M	0.04%	508
2016 Q1	–	Sell	-42,136	Closed	-$3.74M	–	378
2015 Q4	$3.74M	Buy	+42,136	New	+$3.33M	0.27%	94
2015 Q3	–	Sell	-8,674	Closed	-$701K	–	417
2015 Q2	$701K	Buy	+8,674	New	+$565K	0.04%	242

Other funds holding EGRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Voloridge Investment Management's EGRX Position: Q1 2021 in Review

Voloridge Investment Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2021, closing a stake of 8,432 shares — an estimated $393K sold.

Voloridge Investment Management first reported a position in EGRX in Q2 2015 and held it in 7 quarters. The position peaked at $3.74M in Q4 2015. 155 funds tracked by Wall St. Rank hold EGRX as of Q1 2021.

Voloridge Investment Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
Voloridge Investment Management sold 8,432 Eagle Pharmaceuticals, Inc. shares in Q1 2021, an estimated $393K.
Voloridge Investment Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 7 quarters.
Voloridge Investment Management's Eagle Pharmaceuticals, Inc. position peaked at $3.74M in Q4 2015.
155 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2021.

Based on Voloridge Investment Management's 13F filing for Q1 2021, filed 17 May 2021.